Skip to main content
BMC Ophthalmology logoLink to BMC Ophthalmology
. 2024 Nov 8;24:490. doi: 10.1186/s12886-024-03750-w

Glaucoma medication non-adherence rate and associated barriers among glaucoma patients in Hawassa, Ethiopia

Balcha Negese Kebede 1,, Seid Mohammed Seid 1, Biruktayit Kefyalew 1, Eyerus Gesese 1
PMCID: PMC11545621  PMID: 39516767

Abstract

Background

The estimated number peoples aged 40 to 80 years affected with glaucoma were 76.0 million in 2020 and 111.8 in 2040 globally. The estimated number peoples aged 40 to 80 years affected with glaucoma were 76.0 million in 2020 and 111.8 in 2040. This study identified glaucoma medication non-adherence rates and associated barriers among patients with glaucoma attending Hawassa University Comprehensive Specialized Hospital.

Methods

A prospective cross-sectional study was conducted on 340 patients diagnosed with glaucoma who were administered ocular hypotensive medication at least for one week before current visit and those who were diagnosed and prescribed the medication, currently presented to the hospital as new attendant. A systematic random sampling technique was used to select study participants. Data was collected using a validated questionnaire by interviewing patients and reviewing their medical charts from May 01 to November 30, 2022. The collected data checked for completeness, entered to SPSS 22. Descriptive and binary logistic regression analysis were done using the software. The findings were presented using tables and Pie-charts. A p-value ≤ 0.05 was used to indicate statistical significance.

Results

About 340 patients participated in this study with response rate of 90%. More than half of them (59.4%) were male. Mean age of the study participants was 60.2 ± 3.17SD years. The majority came from rural areas (186 (54.71%). Approximately 62.4% of them were with bilateral glaucoma while 47.10% were at advanced stage at least in one eye. The glaucoma non-adherence rate was 54.71% (95% CI; 50.90–58.50). Forgetfulness (AOR 28.32 (95% CI;14.80–54.16), difficulty with schedule AOR 2.52 (95% CI;1.009–6.29), believing eye drops were not effective AOR 6.35 (95% CI;1.17–34.49) and poor self-efficacy AOR 10.96 (95% CI;1.26–95.57) were barriers significantly associated with non-adherence.

Conclusion and recommendation

The nonadherence rate to glaucoma medication among patients with glaucoma attending Hawassa University comprehensive hospital was high (54.71%). Forgetfulness, difficulty with schedule, belief that the drug was not effective and poor self-efficacy were barriers associated with glaucoma medication non-adherence. Health workers better to properly council and inform the patients about the disease nature, goal of treatment, danger of nonadherence to administered medication and mechanism to increase their adherence such as setting reminder.

Keywords: Glaucoma medication non- adherence, Barriers to glaucoma adherence, Ethiopia

Introduction

Glaucoma is the leading cause of non-restorable blindness worldwide [1]. It is a more public health challenge than cataract due to constant loss of productivity as a result of its irreversible sight loss compounded by life-long unnecessary hospital and medication costs [2]. Its burden is increasing over time. Globally, approximately 57.5 million people suffered primary open angle glaucoma(POAG) in 2015 [3]. The estimated number of people aged between 40 and 80 years affected with glaucoma were 76.0 million in 2020 and 111.8 million in 2040 [4].

The prevalence of glaucoma blindness is higher in Africa than in other regions of the world accounting for about 15% of blindness. The prevalence of glaucoma [5] blindness is high probably due to a higher prevalence of the disease and inadequate control [5].

Glaucoma is commonly treated with ocular hypotensive medication. The primary goal of glaucoma treatment is to control progression and prevent early blindness while not restoring lost visual function. Delaying the occurrence of blindness is important to maintain productivity which saves economy of one’s nation. During clinical practice, a number of patients show rapid disease progression while they are being treated which could be due to poor treatment adherence.

Glaucoma medication non-adherence is a problem in both developing and developed nations. The problem is worse in sub-Saharan countries because of poor awareness of the disease’s nature and treatment [58]. In developed nation like USA-poor glaucoma medication adherence rates of up to 29% have been reported [9, 10]. In South Korea, it was 27.% [11] and poor in Africa [12]; mostly around 50–60% most studies [12, 13]. In Ethiopia, a significant number of patients were non adherent to glaucoma medications. The prevalence of glaucoma medication adherence in Ethiopia ranges from 32.5 to 61.4% [1417]. From the reviewed literature, commonly reported barriers to glaucoma medication adherence were decreased self-efficacy [1821], difficulty in instilling drops [18, 19, 22, 23], forgetfulness [18, 19, 22, 23], difficulties with the medication schedule [18, 19, 22, 23], side effects [19, 20, 22, 23], medication cost [19, 2224], mistrust physician [22, 23], belief that glaucoma medication mitigates vision loss [23], and patient health literacy [20]. Although some studies [1417] on glaucoma medication adherence are available in Ethiopia, there is no study that identified specific barrier or groups of barriers significantly associated with glaucoma medication non-adherence in Ethiopia, particularly in Hawassa. Therefore, this study aimed to identify the glaucoma non-adherence rate and associated barriers among patients with glaucoma attending Hawassa University comprehensive specialized hospital (HUCSH). It is important to plan community-oriented measures to increase adherence to glaucoma medication and reduce the burden of blindness due to glaucoma.

Objectives of the study

General objective

To determine glaucoma medication non-adherence rates and associated barriers among patients with glaucoma attending Hawassa University comprehensive specialized hospital.

Methods

Study design, study area, and period

A hospital-based cross -sectional study was conducted at HUCSH, which is located in Hawassa city, around 275 Km South of Addis Ababa, Ethiopia. The study was conducted from May 01 to November 30, 2022.

Study population

All patients with glaucoma treated with ocular hypotensive medication during follow-up presented at HUCSH Ophthalmic OPD during the data collection period.

Inclusion and exclusion criteria

All selected patients with glaucoma on follow-up at the HUSCH during the data collection period were included in the study. All patients with glaucoma who were treated surgically, mentally incompetent, or unable to communicate were excluded from the study.

Sample size determination

graphic file with name M1.gif

By taking proportion (P) glaucoma medication non-adherence study at Bahir Dar Felege Hiwot specialized Hospital 56. % [11] for sample size calculation, the calculated sample size was 378.

Sampling technique

From pattern glaucoma patient flow to the hospital the estimated number of eligible patients with glaucoma attending the hospital was 1896. Daily, approximately 12 eligible glaucoma patients would visit the clinic. A systematic random sampling technique with a sampling fraction K = 5(1896/378) was used. Order patients medical charts arrival to the glaucoma clinic was used as sampling frame. The first study participant was selected using the lottery method from the first five patients with glaucoma who visited the glaucoma clinic on the starting day of data collection. Then every 5th glaucoma patient on ocular hypotensive medication was selected.

Operation definition

The medication adherence rate was calculated based on Martin.et al. [25], using the following formula:

graphic file with name M2.gif

Adherence: Patients with a glaucoma who scored medication adherence rate ≥ 80% was considered adherent and scored < 80% considered non adherent [25].

Data collection and quality control

The structured questionnaire containing socio-demographic, list of possible barriers, drug adherence questions and pattern of glaucoma. Data about pattern of glaucoma was reviewed from the patients chart while other information were obtained interviewing patients. The questionnaire was pretested for reliability and validity in 5% of the total sample size of glaucoma patients attending Yirgalem hospital and was assessed for its clarity, completeness and reliability. Its reliability was assessed by computing Cronbach alpha which was 0.76. The questionnaire was translated to a local language by a language expert for data collection and then retranslated to English after data collection. The data was collected interviewing study participants using the structured questionnaire, and reviewing their medical charts.

Data processing and analysis

The collected data were checked for completeness and incomplete data were excluded from the analysis and considered non-respondents because they were not provided full data. The complete data entered in to SPSS 22. Descriptive analysis and binary logistic regression were performed; the findings are presented in text, tables, and a pie chart. Covariates with a P-value of less than 0.05 in the multivariable logistic regression were considered statistically significant.

Results

Approximately 340 patients participated in this study, and the response rate was 90%. More than half of them were male (59.4).Mean age of the study participants was 60.2 ± 3.17SD years. The majority came from rural areas (186 (54.7%). About 156 (45.9%) had no formal education. A greater proportion of study participants were housewives of 90(26.5%), followed by farmers of 86(25.3%). More than half (64.71%) of the participants traveled two hours or more to the hospital (Table 1).

Table 1.

Socio-demographic characteristics of study participant (n = 340)

Variable Frequency Percentage
Age
 ≤ 40 32 9.41
 41–50 77 22.65
 51–60 125 36.76
 >60 106 31.18
Sex
 Male 202 59.4
 Female 138 40.6
Residence
 Urban 154 45.3
 Rural 186 54.7
Marital status
 Single 16 4.7
 Married 248 72.9
 Widowed 74 21.8
 Divorced 2 0.6
Educational status
 No formal education 156 45.9
 Primary 92 27.1
 Secondary 32 9.4
 College or higher 60 17.6
Occupation
 Household (wife) 90 26.5
 Governmental 36 10.6
 Farmer 86 25.3
 Merchant 56 16.5
 Retired 48 14.1
 Another 24 7
Distance from hospital (hr.)
 <1 h 59 17.35
 1–2 h. 61 17.94
 2–3 h. 142 41.77
 >3 h. 78 22.94
Pattern of glaucoma
Type
POAG 220 64.70
PEXG 104 30.60
Others(NTG, NVG etc.) 14 4.70
stage of glaucoma
Mild 50 14.70
Moderate 130 38.20
Advanced 160 47.10
Laterality
Unilateral 128 37.60
Bilateral 212 62.40

Glaucoma medication nonadherence rate

The rate of glaucoma medication non-adherence in this study was 186/340 [54.71% (95% CI: 50.90–58.5)]. Only 45.29% of respondents were adherent. See Fig. 1.

Fig. 1.

Fig. 1

Proportion of adherence to glaucoma medication among patients with glaucoma attending HUCSH

Reported barriers to glaucoma medication adherence

Overall 285(83.9%) patients reported at least one barrier to glaucoma medication adherence. About 55(16.17%) participants selected no barrier. Out of those reported no barriers noticed, 96.36% were adherent; however, 52.17%( 48/92) of those who selected one barrier were adherent, and 72.54%( 140/193) of those who selected more than one barrier were non-adherent (Table 2).

Table 2.

Showing number barriers and glaucoma adherence

Adherent n(%) Non-adherent
n (%)
Total
n (%)
Not selected 53(96.36) 2(3.64) 55(16.17)
Selected one barrier 48(52.17) 44(47.83) 92(27.06)
Selected two or more barriers 53(27.46) 140(72.54) 193(56.77)
Total 154(45.29) 186(54.71) 340(100)

Overall forgetfulness 200(58.8%), medication cost 116(34.1%), and life stress 88 (25.9%) were the top three barriers to glaucoma medication adherence respectively (Table 3).

Table 3.

Associated barriers to glaucoma medication nonadherence

Selected barriers Non adherent Adherent 95% confidence interval (CI) CORCI COR p-value 95% AOR P-value
Forgetfulness
Selected as the barrier 166 34 29.29(16.07–53.39) 0.001 28.32(14.80-54.16) 0.001
Not selected 20 120 1.00
Medication cost
Selected as the barrier 28 88 2.06(1.61–2.53) 0.002 1.88(0.96.-3.67) 0.06
Not selected 30 194 1.00 1.00
Life stress
Selected as the barrier 52 36 1.64(0.78–2.080) 0.338 1.27(0.778–2.08) 0.118
Not selected 118 134 1`0.00 1.00
Difficulty with schedule
Selected as the barrier 54 21 5.89(2.882–12.041) 0.001 2.52(1.009–6.29) 0.048
Not selected 81 185 1.00 1.00
Believe glaucoma does not cause vision loss
yes 34 10 3.22(1.54–6.76) 0.002 2.53(0.87–7.35) 0.088
No 152 144
Believe that eye drops are not effective
Yes 28 4 6.65(2.28–19.40) 0.001 6.35(1.17–34.49) 0.032
No 158 150
Poor self-efficacy
Yes 162 152 11.26(2.62–48.45) 0.001 10.96(1.26–95.57) 0.030
No 24 2
Poor knowledge about glaucoma
Yes 16 6 2.32(0.89–6.09) 0.087 1.87(0.35–10.08) 0.58
No 170 148
Mistrust physician
Yes 162 152 11.26(2.62–48.45) 0.001 5.16(0.73–36.65) 0.101
No 24 2 1/00 1.00
Difficulty in instilling eye drops
Yes 48 2 26.44(6.31–110.8) 0.000 1.72(0.68–4.39) 0.045
No 138 152
Side effects of medication
Yes 26 2 12.35(2.88–52.93) 0.001 1.56(0.29–8.28) 0.603
No 160 152

Barriers associated with glaucoma medication nonadherence

Binary logistic regression of univariate analysis indicate that miss perception of glaucoma not blinding disease and belief eye drops cannot effectively treating glaucoma were significantly associated with glaucoma medication non adherence. Physical and health related barriers such poor self-efficacy, difficulty in instilling eye drops and forgetfulness were identified as barriers significantly affecting the adherence. The other factors observed to affect adherence were mistrust of physician, medication side effect and cost, and difficulty with medication schedule.

In the multivariable analysis, forgetfulness, difficulty with medication schedule, belief that the eye drops are not effective for treating glaucoma, and poor self-efficacy were significantly associated with non-adherence to glaucoma medication. Those who mentioned forgetfulness as a barrier were 28.32-fold more likely to be non-adherent to the medication. Similarly, those who stated difficulty with scheduling as a barrier were 2.52 times more likely to be non-adherent. Those who believe that eye drops are not effective for treating glaucoma were also 6.35 times more likely to be non-adherent to glaucoma medication. On the other hand, individuals with poor self- efficacy were 10 times more likely to be non-adherent (Table 3).

Discussion

Glaucoma medication non-adherence rate in this study was 54.71%. Only 45.29% were adherent to their prescribed anti-glaucoma medication. The non-adherence rate in this study is higher than that in studies in Nigeria 36.8% [26], Pakistan(Al-Shifa Trust Eye Hospital (ASTEH)) 30% [27]. The reason for disparity between current study and that of Nigeria was due to difference in age of the study participants.

It was lower than studies in the US community (71% [9, 10], South Korea 73% [11], Oman 75.24% [28] and Australia (58.6%) [29]. The difference was due time of the study and age of the study participants, majority of the study participants in the previous studies were older individuals compared to current study. Forgetfulness which as among the top three barriers identified reported in this study increase with age because degenerative condition of the brain such as dementia and Alzaimers increase with age. Similarly, non-adherence to glaucoma medication was lower than the finding in a study in Jima, Ethiopia which was 67.5% [17]. The difference was due to some difference in the operational definition, socio economic and some cultural practice that could affect perception towards the disease and eye drops can account for the deference. It was higher than observations of studies in Ghana 41.7% [12], Nigeria 44.4% [13] and Gondar 44.4%, Bahir dar 43.8% Ethiopia respectively [13, 15, 16].

The most frequently reported barrier for non-adherence to glaucoma medication in this study was forgetfulness (89.25%) among non-adherent. Those who mentioned forgetfulness as a barrier were 28 times more likely to be non-adherent to medication. Similarly, those who stated difficulty with schedule and life stress as barriers were 2.52 and 1.88 times more likely to be non-adherent, respectively. Forgetfulness was similarly reported as the main barrier in studies conducted in the USA (glaucoma clinics in Ann Arbor, Michigan and Baltimore, Maryland), Vanderbilt Eye Institute, and systematic review of glaucoma adherence [18, 19, 22, 23, 30]. The most frequently cited barrier by adherents was the cost of the medication (57.14%); because ant glaucoma medications are lifelong treatment. Cost and life stress have also been similarly reported as barriers in previous studies in the USA [1518, 20] and systematic reviews of different ligatures [19].

Significant number of patients reported cost of medication as a barrier to glaucoma medication adherence. However it was not significantly associated with the non-adherence. This implies that most of the patients were willing to pay for the medication compromising other expenses. It also indicate that many people are wasting medication they bought due their miss perception about the disease and the eye drops effectiveness seeking restoration of lost vision.

In the multivariable analysis, forgetfulness, difficulty with medication schedule, belief that the eye is not effective for treating glaucoma, and poor self-efficacy were significantly associated with non-adherence to glaucoma medication. Those who mentioned forgetfulness as a barrier were 28.32-fold more likely to be non-adherent to medication. Similarly, those who stated difficulty with scheduling as a barrier were 2.52 times more likely to be non-adherent. This finding is similar to that of a study in Brazil [30]. Those who believe that eye drops are not effective for treating glaucoma were also 6.35 times more likely to be non-adherent to glaucoma medication. On the other hand, individuals with poor self- efficacy were 10 times more likely to be non-adherent.

Conclusions and recommendations

The nonadherence rate to glaucoma medication among patients with glaucoma attending Hawassa University comprehensive hospital was high (54.71%). Forgetfulness, difficulty with schedule, belief that the drug was not effective and poor self-efficacy were associated barriers to glaucoma medication non-adherence in Hawassa. Holistic approach to increase glaucoma medication including but not limited to setting up reminder, prescribing medication with low frequency of application, awareness creation on the effectiveness of eye medication are needed to increase adherence to glaucoma medication. It is also better to conduct study on how to minimize the identified barriers. Limitations of this study - Recall bias is the main limitation of the study since subjects were asked to remember days they missed to apply their prescribed medication.

Acknowledgements

Our deepest gratitude goes data collectors Hawassa University graduating class optometry students.

Abbreviations

HUCSH

Hawassa University Comprehensive Specialized Hospital

IOP

Intraocular pressure

OPD

Outpatient department

MSc

Master of Science

hr

hour

COR

Crude odds ratio

AOR

adjusted odds ratio

Author contributions

In conducting this research BN provided conception, designed and developed manuscript and ensured that all authors approved the manuscript before submission.BK supervised data collection and organized the data, made analysis and interpretation of the data. SM designed the study and revised data analysis, gave professional consultation and comment. EG assessed data quality, entered data to SPSS, provided scientific concepts to the study and write discussion.Finally all authors made substantial contribution for important intellectual concept. Finally gave approval of the version to be published; agree to accountable for all aspects of the work.

Funding

The research did not receive any specific grant from funding agencies in the public commercial or not for profit sectors.

Data availability

Database from which analysis made available on request from Seid Mohammed/ email: seidopto@gmail.com.

Declarations

Ethics approval and consent to participate

The research was conducted according to the Declaration of Helsinki. All reported findings were obtained by analyzing interview data; no experiments or physical examinations were performed for the study participants. The study was approved by the Hawassa University School of Medicine Research Committee, and ethical clearance was obtained. The objective and purpose of our study were explained to the patients, and written informed consent was obtained from each participant before beginning the interview. Informed consent for those who could not read and write was obtained from their parents or legal guardians. Only those who provided consent and were willing to participate were interviewed. To ensure confidentiality, the respondents were not asked to write their names at the time of interview. Consent to declare that participant’s participation is voluntary. They were also informed there was no risk associated with refusal to participate and had the right to draw at any time they wished. They also have a full right to contact and ask authors what they want.

Consent to publish

Consent for publication was not applicable for this study because the study did not include any individual data.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Parihar J, Glaucoma. The ‘Black hole’of irreversible blindness. Med J Armed Forces India. 2016;72(1):3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kingman S. Glaucoma is the second leading cause of blindness globally. Bull World Health Organ. 2004;82:887–8. [PMC free article] [PubMed] [Google Scholar]
  • 3.Kapetanakis VV, Chan MP, Foster PJ, Cook DG, Owen CG, Rudnicka AR. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2015. [DOI] [PMC free article] [PubMed]
  • 4.Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90. [DOI] [PubMed] [Google Scholar]
  • 5.Kyari F, Adekoya B, Abdull MM, Mohammed AS, Garba F. The current status of glaucoma and glaucoma care in sub-saharan Africa. Asia-Pacific J Ophthalmol. 2018;7(6):375–86. [DOI] [PubMed] [Google Scholar]
  • 6.Abdull MM, Gilbert CC, Evans J. Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment. BMC Ophthalmol. 2015;15:1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Chauke GD, Nakwafila O, Chibi B, Sartorius B, Mashamba-Thompson T. Factors influencing poor medication adherence amongst patients with chronic disease in low-and-middle-income countries: a systematic scoping review. Heliyon. 2022. [DOI] [PMC free article] [PubMed]
  • 8.Adekoya B, Adepoju F, Moshood K, Balarabe AH. Challenges in the management of glaucoma in a developing country; a qualitative study of providers’ perspectives. Niger J Med. 2015;24(4):315–22. [PubMed] [Google Scholar]
  • 9.Sleath B, Blalock SJ, Covert D, Skinner AC, Muir KW, Robin AL. Patient race, reported problems in using glaucoma medications, and adherence. International Scholarly Research Notices. 2012;2012.
  • 10.Feehan M, Munger MA, Cooper DK, Hess KT, Durante R, Jones GJ, et al. Adherence to glaucoma medications over 12 months in two US community pharmacy chains. J Clin Med. 2016;5(9):79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kim CY, Park KH, Ahn J, Ahn M-D, Cha SC, Kim HS et al. Treatment patterns and medication adherence of patients with glaucoma in South Korea. Br J Ophthalmol. 2017. [DOI] [PMC free article] [PubMed]
  • 12.Driessen S, Nelson-Ayifah D, Ampong A, Klaver CC, Bonnemaijer PW, Thiadens AA. Risk factors for compliance to medication in African glaucoma patients. Investig Ophthalmol Vis Sci. 2022;63(7):1636–A0131. -1636–A0131. [Google Scholar]
  • 13.Bello SI, Ojieabu WA, Yusuf H. Drug utilization, medication adherence and treatment satisfaction amongst glaucoma patients receiving care at secondary health facilities. J Pharm Health Serv Res. 2023;14(1):71–8. [Google Scholar]
  • 14.Melaku MW, Yibekal BT, Demilew KZ. Adherence to topical anti-glaucoma medications in Sidama regional state, Southern Ethiopia. PLoS ONE. 2023;18(4):e0284200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Anbesse DH, Yibekal BT, Assefa NL. Adherence to topical glaucoma medications and associated factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia. Eur J Ophthalmol. 2019;29(2):189–95. [DOI] [PubMed] [Google Scholar]
  • 16.Assem AS, Fekadu SA, Yigzaw AA, Nigussie ZM, Achamyeleh AA. Level of glaucoma drug adherence and its associated factors among adult glaucoma patients attending felege hiwot specialized hospital, Bahir Dar City, Northwest Ethiopia. Clinical optometry. 2020:189 – 97. [DOI] [PMC free article] [PubMed]
  • 17.Tamrat L, Gessesse GW, Gelaw Y. Adherence to topical glaucoma medications in Ethiopian patients. Middle East Afr J Ophthalmol. 2015;22(1):59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Gatwood J, Brooks C, Meacham R, Abou-Rahma J, Cernasev A, Brown E, et al. Facilitators and barriers to glaucoma medication adherence. J Glaucoma. 2022;31(1):31–6. [DOI] [PubMed] [Google Scholar]
  • 20.Sleath BL, Blalock SJ, Muir KW, Carpenter DM, Lawrence SD, Giangiacomo AL, et al. Determinants of self-reported barriers to glaucoma medicine administration and adherence: a multisite study. Ann Pharmacother. 2014;48(7):856–62. [DOI] [PubMed] [Google Scholar]
  • 21.Muir KW, Rosdahl JA, Hein AM, Woolson S, Olsen MK, Kirshner M, et al. Improved glaucoma medication adherence in a randomized controlled trial. Ophthalmol Glaucoma. 2022;5(1):40–6. [DOI] [PubMed] [Google Scholar]
  • 22.Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002;18(5):401–9. [DOI] [PubMed] [Google Scholar]
  • 23.Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12(5):393–8. [DOI] [PubMed] [Google Scholar]
  • 24.Friedman DS, Hahn SR, Gelb L, Tan J, Shah SN, Kim EE, et al. Doctor–patient communication, health-related beliefs, and adherence in glaucoma: results from the glaucoma adherence and persistency study. Ophthalmology. 2008;115(8):1320–7. e3. [DOI] [PubMed] [Google Scholar]
  • 25.Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36–44. [DOI] [PubMed] [Google Scholar]
  • 26.Ngozi oNwubikoA S, zuada NwachukwuA N. Glaucoma medications: issues with adherence in a tertiary hospital in Nigeria. Family Med Prim Care Rev. 2020;22(4):302–6. [Google Scholar]
  • 27.Munir H, Sadiq M, Khan S, Zafar S, Akhtar F. Factors Associated with Non-compliance to Long term Glaucoma medication in a developing country. Pakistan J Ophthalmol. 2022;38(3).
  • 28.Khandekar R, Shama ME-S, Mohammed AJ. Noncompliance with medical treatment among glaucoma patients in Oman—a cross-sectional descriptive study. Ophthalmic Epidemiol. 2005;12(5):303–9. [DOI] [PubMed] [Google Scholar]
  • 29.Mc Clelland JF, Bodle L, Little J-A. Investigation of medication adherence and reasons for poor adherence in patients on long-term glaucoma treatment regimes. Patient Prefer Adherence. 2019:431–9. [DOI] [PMC free article] [PubMed]
  • 30.Costa Andrade J, Motta GS, Kasahara N. Perspectives on adherence to Glaucoma medical therapy in Brazilian patients. Pharm Med. 2023:1–8. [DOI] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Database from which analysis made available on request from Seid Mohammed/ email: seidopto@gmail.com.


Articles from BMC Ophthalmology are provided here courtesy of BMC

RESOURCES